Treatment with neutralizing antibodies for these cytokines reduce the susceptibility of Atg16L1 deficient mice to DSS induced colitis, indicating the importance of Atg16L1 in the suppression of intestinal inflammation [63]. The gene discussed is ATG16L1; the disease is colitis.